StudyFinder
HM2023-43: A phase 2 trial of tafasitamab in combination with lenalidomide+rituximab in treatment-naive follicular lymphoma and marginal zone lymphoma
Status: Recruiting
This study is to see if patients who get tafasitamab in addition to the standard regimen of lenalidomide and rituximab when they are just starting treatment are more likely to stay in remission after treatment than those who do not. We expect that participants will be in this research study for approximately 3 years total. Patients will be on active treatment for approximately 1 year.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• confirmed marginal zone lymphoma
• have not received systemic therapy for lymphoma
• need treatment because of bulky disease, associated symptoms, or causing problems with vital organs (heart, spleen, lung)
• see link to clinicaltrials.gov for complete Inclusion criteria
Exclusion Criteria:
• active HIV, Hepatitis B, Hepatitis C
• prior history of lenalidomide use
• history of another cancer in the past 5 years
• women who are pregnant or breastfeeding
• see link to clinicaltrials.gov for complete Exclusion criteria
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Follicular Lymphoma
Study Contact: Sanjal Desai - desai171@umn.edu
Principal Investigator: Sanjal Desai
Phase: PHASE2
IRB Number: STUDY00023899
See this study on ClinicalTrials.gov